Search bioRxiv⌕ Search

Biology subjects

Lopes, C. F. B.

Publications and source records attributed to Lopes, C. F. B..

2 recordsLinked to original sources

Cold acclimation reprograms hepatic lipid composition toward n-3 HUFAs to uncouple adipose-derived lipid flux from steatosis

While cold exposure drives lipid flux from adipose tissue to the liver, this enhanced inter-organ crosstalk does not result in sustained hepatic steatosis during prolonged acclimation, indicating that factors beyond lipid flux shape metabolic outcome. To interrogate this adaptation, we performed integrated lipidomic and metabolic profiling across tissues and circulating lipoproteins over the course of cold acclimation. We showed that cold acclimation induces systemic reprogramming of lipid quality in mice, characterized by enrichment of n-3 highly unsaturated fatty acids (HUFAs) as a consequence of upregulation of fatty acid desaturases (FADS1 and 2) in the liver and white adipose tissue, thus increasing hepatic n-3/n-6 ratio. Cold-induced increase in n-3 HUFAs cause the suppression of SCD1-mediated desaturation, thus yielding a depletion of monounsaturated fatty acids (MUFAs) in the liver, along with the suppression of lipogenic markers. Notably, this high-HUFA/low-MUFA lipid signature is present in both hepatic free fatty acid and triglyceride pools, indicating that lipid remodeling occurs upstream of triglyceride synthesis. Lipidomic analysis revealed that the remodeled triglycerides are incorporated into very-low-density and intermediate density lipoproteins (VLDL and IDL), thereby propagating hepatic lipid reprogramming to the circulation. Thus, by selectively increasing endogenous n-3 HUFA availability, cold adaptation suppresses hepatic DNL and MUFA-driven triglyceride assembly, buffering lipid accumulation despite sustained fatty acid influx and reshaping systemic lipid distribution with potential cardiometabolic impact.

biochemistry↗

Antinociceptive synergy in a peripheral hyperalgesia model: interplay of cannabinoidergic, adrenergic, and opioidergic systems and their antagonism

There is growing interest in co-administering know analgesics for pain management, to reduce side effects and maximize therapeutic effects by pharmacological synergism, defined as supra-additive effects to biological stimuli. This work aimed to evaluate, using isobolgraphic analysis, synergistic effects of three antinociceptive substances-- anandamide (AEA), a cannabinoid CB1 receptor agonist; xylazine (XYL), an adrenergic 2-receptor agonist; and DAMGO, an {micro}-opioid receptor agonist--administered in binary doses in a prostaglandin E2 (PGE2)-induced peripheral pain model. Hyperalgesia was induced in Swiss male mice, and subsequently, animals were treated with binary agonist combinations administered to the hind paw. Mechanical nociceptive thresholds were measured using an algesimetric task, and the results obtained were compared with additive predicted effects. For AEA+XYL and AEA+DAMGO combinations, the observed effects were significantly greater than those predicted by Loewes additivity principles at all tested effect levels (10%, 30%, and 50% maximum possible effect, MPE). DAMGO+XYL combination showed significant synergistic effects at 10% and 30% MPE but not at 50% MPE. Confirming these findings, combination indexes (CI) for AEA+XYL and AEA+DAMGO were less than 1, indicating synergism, while CI for DAMGO+XYL was near 1, indicating additivity. Notably, single-system antagonism with either AM251, a CB1 antagonist, yohimbine, an 2C-receptor antagonist or naloxone, pan-opioid receptor antagonist, could prevent synergy or any analgesia at all for AEA+XYL and AEA+DAMGO. Furthermore, the binary agonist combinations did not produce systemic effects, sedation, or motor impairments. The results suggest synergistic antinociceptive effects for AEA+XYL and AEA+DAMGO, which are dependent on concomitant agonism upon known metabotropic receptors.

pharmacology and toxicology↗